Keiji AI

What Keiji AI does

Keiji AI is a US-based, privately held artificial intelligence company that develops TrialMind, an agentic AI platform for the full clinical trial lifecycle. The platform targets pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic medical centers, with named enterprise customers including AbbVie, Regeneron, Takeda, Guardant Health, Beth Israel Deaconess Medical Center, and Alumis, plus an academic deployment at the University of Nevada, Reno School of Medicine. Founded in 2023 and currently operating with 1-10 employees, the company is venture-backed and incorporated as KEIJI AI, Inc. in the United States.

The technical foundation is the Panacea foundation model, trained on more than 1 million clinical trial records, augmented by 100+ proprietary Model Context Protocol (MCP) tools and 10+ specialized AI agents covering six clinical research stages: discovery, planning, initiation, execution, analysis, and reporting. Distinct AI assets include TrialGPT (patient-trial matching achieving 87% expert-level accuracy, published in Nature Communications), LEADS (medical literature mining), AutoTrial (LLM for protocol design), HINT and SPOT (outcome prediction), FRAMM (fair site ranking), and TrialPanorama, a structured database aggregating 1.6M clinical trials from 15 global registries linked with DrugBank, MedDRA, RxNorm, MeSH, and PubMed. The platform also includes a Digital Twin simulation module and supports biostatistics programming, regulatory writing, and risk-based monitoring. Keiji AI reports 100+ peer-reviewed publications in Nature, Nature Biomedical Engineering, Nature Communications, and NeurIPS, and cites benchmark gains of 1.2×-12× over general-purpose LLMs across biomedical reasoning tasks.

The business model is enterprise SaaS: subscription-based, quote-priced, and sold via a "Book a Demo" sales motion. The company reports multi-million-dollar ARR and 5× year-over-year growth, with security and compliance certifications including SOC 2 Type 1 and Type 2, HIPAA, GxP, and ISO 27001 enabling procurement inside regulated pharma environments. Revenue is concentrated across a small number of enterprise accounts, and go-to-market is direct enterprise field sales without channel partners. Strategic academic co-development partnerships with the University of Illinois Urbana-Champaign, NIH, the University of Edinburgh / Health Data Research UK, and UNR Med function as both research collaborators and reference customers.

Name

Keiji AI

Legal name

KEIJI AI, Inc.

Website

https://keiji.ai

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Keiji AI provides TrialMind, an agentic AI platform that automates clinical trial design, patient recruitment, site selection, monitoring, biostatistics, and regulatory writing for pharmaceutical companies, biotechnology firms, CROs, and academic medical centers, built on a proprietary foundation model and clinical trial knowledge base.

Ownership category

akta.pro rank

Product category

AI Clinical Trial Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design Services (541512)

SIC

Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN), Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Clinical trial software
• AI drug discovery
• Patient recruitment AI
• Clinical data analysis
• Trial design automation

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. TrialMind Platform Subscription: SaaS platform subscription model for enterprise customers including pharmaceutical companies, biotech firms, CROs, and academic medical centers. Multi-million-dollar ARR and 5× YoY growth indicate significant enterprise contract values. Pricing is quote-based, suggesting tiered enterprise plans.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Keiji AI develops and sells TrialMind, an end-to-end agentic AI platform for the clinical trial lifecycle. The platform supports discovery, trial design, real-world data analysis, site selection, patient recruitment, data monitoring, biostatistics, outcome prediction, literature review, and regulatory writing via 10+ specialized AI agents and 100+ proprietary Model Context Protocol (MCP) tools backed by 1M+ clinical trial data records. It is offered as a SaaS subscription to enterprise pharmaceutical, biotech, CRO, and academic medical center customers, with regulatory-grade security (SOC 2, HIPAA, GxP, ISO 27001).

Product overview

Keiji AI offers TrialMind, an end-to-end agentic AI platform for clinical trial lifecycle management. The platform comprises a core TrialMind Platform with 10+ specialized AI agents, 100+ MCP tools, and 1M+ trial data, organized across 6 stages: Discovery (Target & Mechanism Discovery), Planning (Real-World Data Analysis, Trial Design, Digital Twin), Initiation (Site Selection, Patient Recruitment), Execution (Data Monitoring, Safety Signal Analysis), Analysis (Biostat Analysis & Programming, Outcome Prediction, Trial Intelligence), and Reporting (Literature Review, Regulatory Writing). Key specialized models include TrialGPT for patient-trial matching, LEADS for literature mining, TrialPanorama database (1.6M trials), and AutoTrial for protocol generation. The platform supports enterprise customers including top 20 pharma, biotech, CROs, and academic medical centers.

Differentiator

Problem solved

Functional benefit

Brands

• TrialMind: AI agents platform for the clinical trial lifecycle, supporting trial design, initiation, execution, analysis, and reporting. Features 100+ MCP tools and supports all 6 clinical research stages.
• TrialPanorama
• TrialGPT

Products and services

• TrialMind Platform End-to-end agentic AI platform for the clinical trial lifecycle covering discovery, planning, initiation, execution, analysis, and reporting. Powers 10+ specialized AI agents with 100+ MCP tools and access to 1M+ trial data for enterprise clinical research teams.
• TrialGPT Large language model specialized for patient-trial matching that processes eligibility criteria against patient notes, retrieves relevant trials, and provides criterion-level explanations with evidence citations. Achieves 87% expert-level accuracy with ~43% screening-time savings.
• LEADS Foundation model for medical literature mining trained on ~20K systematic reviews and 400K+ clinical trials, integrating human expertise with AI-driven screening to automate systematic literature reviews and evidence synthesis.
• TrialPanorama Large-scale structured resource aggregating 1.6M clinical trial records from 15 global registries linked with biomedical ontologies (DrugBank, MedDRA, RxNorm, MeSH, PubMed), packaged with 8 benchmark tasks for clinical research AI evaluation.
• AutoTrial First large language model specialized for clinical trial design, trained on 400K+ clinical trial records and 300K instructional data points to rapidly generate accurate, regulatory-compliant eligibility criteria for trial protocols.
• SPOT Model Sequential predictive modeling of trial outcomes using meta-learning to dynamically forecast early-phase clinical trial outcomes with up to 21.5% better prediction accuracy than baseline approaches.

Quantifiable outcome

• TrialMind outperforms general-purpose LLMs by 1.2×-12× across biomedical reasoning benchmarks (HLE-Medicine, LabBench-LitQA2, SuperGPQA-Hard, Target Identification, MOA & Pathway Reasoning)
• +4 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability12 records

Feature12 records

Partnerships

Five partnerships are on record, tiered core and notable.

• University of Illinois Urbana-ChampaigncoreStrategic or Co-development PartnerCo-authorship on TrialPanorama research paper with faculty from UIUC's University of Illinois Urbana-Champaign. Collaboration on foundational AI research for clinical trial databases and benchmarks.
• National Institutes of Health (NIH)coreStrategic or Co-development PartnerCo-authorship on TrialPanorama paper with NIH researchers (Zhiyong Lu). Collaboration on integrating clinical trial data with biomedical ontologies and literature.
• University of EdinburghcoreStrategic or Co-development PartnerAcademic collaboration on TrialPanorama research with researchers from University of Edinburgh and Health Data Research UK.
• University of Nevada, Reno School of Medicine (UNR Med)coreStrategic or Co-development PartnerFirst medical school to integrate TrialMind directly into curriculum (IDEA Project). UNR Med uses TrialMind for teaching evidence-based medicine to first-year medical students.
• Nature Publishing GroupnotableOthersPeer-reviewed publications in Nature journals (Nature Biotechnology, Nature Biomedical Engineering, Nature Communications) establishing scientific credibility and thought leadership.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Saama Technologies: Saama provides AI-driven clinical development and life sciences analytics platforms (e.g., Life Science Analytics Cloud) that compete head-on with Keiji's TrialMind across trial design, patient recruitment, and operational analytics for pharma and CRO customers.
• Deep 6 AI: Deep 6 AI focuses on AI-powered patient-trial matching and clinical trial acceleration using EHR mining, directly overlapping with Keiji's TrialGPT and Patient Recruitment modules.
• ConcertAI: ConcertAI offers AI and real-world evidence solutions for clinical research, trial design, and patient recruitment in oncology and other therapeutic areas, competing with Keiji across RWD analysis, trial design, and outcome prediction.
• Mendel: Mendel applies LLMs and AI to clinical trial matching and biomedical document understanding, closely mirroring Keiji's TrialGPT and LEADS offerings for pharma and health system customers.
• Owkin: Owkin applies AI and federated learning to biomedical research and clinical development, including trial design and biomarker discovery, competing with Keiji's Discovery and trial outcome prediction capabilities for pharma customers.

Broad incumbents

• Medidata Solutions (Dassault Systèmes): Medidata is the dominant EDC/CTMS/EDC platform for clinical trials, now embedding AI across its suite. It competes with Keiji across trial design, data monitoring, biostatistics, and patient engagement, with deep enterprise penetration that Keiji must displace.
• Veeva Systems: Veeva is the leading cloud software provider for life sciences across CRM, regulatory, quality, and clinical data management. Veeva's clinical and regulatory suites compete with Keiji's Regulatory Writing, RIM-adjacent, and trial operations modules inside top-20 pharma.
• IQVIA: IQVIA combines the world's largest CRO with a technology and analytics platform (e.g., E360, OCE) that competes with Keiji across trial design, RWD analytics, patient recruitment, and outcome prediction for pharma and biotech.
• Tempus Labs: Tempus combines multimodal data, AI, and a clinical trial platform (e.g., TIME) for precision medicine and trial matching. It competes with Keiji on real-world data analysis, patient recruitment, and trial intelligence across oncology and broader therapeutic areas.

Emerging players

• Trial Library: Trial Library is an AI-native clinical trial design and feasibility platform focused on protocol optimization and site selection, overlapping with Keiji's Trial Design, Digital Twin, and Site Selection modules.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/keiji_ai_inc
• YouTubeyoutube.com/@AIforhealth
• LinkedInlinkedin.com/company/keiji-ai-inc

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Keiji AI